First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial

P0066 A randomised phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer

European Journal of Cancer ◽

10.1016/j.ejca.2014.03.110 ◽

2014 ◽

Vol 50 ◽

pp. e27 ◽

Cited By ~ 1

Author(s):

J.C-H. Yang ◽

K. Park ◽

T. Mok ◽

J.H. Kang ◽

V. Srimuninnimit ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

East Asian ◽

Locally Advanced ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Asian Patients ◽

A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8041 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8041-8041 ◽

Cited By ~ 1

Author(s):

James Chih-Hsin Yang ◽

Vichien Srimuninnimit ◽

Myung-Ju Ahn ◽

Chia-Chi Lin ◽

Sang-We Kim ◽

...

Keyword(s):

Lung Cancer ◽

East Asian ◽

Locally Advanced ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Asian Patients ◽

Final Survival ◽

Phase 3 study of first-line crizotinib vs pemetrexed−cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.9058 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 9058-9058 ◽

Cited By ~ 5

Author(s):

Shun Lu ◽

Tony Mok ◽

You Lu ◽

Jianying Zhou ◽

Yuankai Shi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

East Asian ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Asian Patients ◽

First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non–Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study

10.1016/j.jtho.2015.11.008 ◽

2016 ◽

Vol 11 (3) ◽

pp. 370-379 ◽

Cited By ~ 8

Author(s):

James Chih-Hsin Yang ◽

Vichien Srimuninnimit ◽

Myung-Ju Ahn ◽

Chia-Chi Lin ◽

Sang-We Kim ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Maintenance Therapy ◽

East Asian ◽

Locally Advanced ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Never Smoker

Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

Clinical Lung Cancer ◽

10.1016/j.cllc.2016.04.003 ◽

2016 ◽

Vol 17 (5) ◽

pp. e103-e112 ◽

Cited By ~ 7

Author(s):

Shun Lu ◽

Ying Cheng ◽

Cai-cun Zhou ◽

Jie Wang ◽

James Chih-Hsin Yang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Meta Analysis ◽

East Asian ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Asian Patients ◽

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

10.1016/j.jtho.2018.06.012 ◽

2018 ◽

Vol 13 (10) ◽

pp. 1539-1548 ◽

Cited By ~ 34

Author(s):

Yi-Long Wu ◽

Shun Lu ◽

You Lu ◽

Jianying Zhou ◽

Yuan-kai Shi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

East Asian ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Asian Patients ◽

Alk Positive ◽

P70.01 Distribution of CCND1 Mutations in East Asian Patients With Non-Small Cell Lung Cancer

10.1016/j.jtho.2021.01.1012 ◽

2021 ◽

Vol 16 (3) ◽

pp. S562-S563

Author(s):

H. Feng ◽

C. Xu ◽

W. Wang ◽

D. Wang ◽

Y. Zhu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

East Asian ◽

Small Cell ◽

Small Cell Lung ◽

Asian Patients ◽

P70.09 NOTCH1 Mutations in East Asian Patients With Non-Small-Cell Lung Cancer

10.1016/j.jtho.2021.08.718 ◽

2021 ◽

Vol 16 (10) ◽

pp. S1214

Author(s):

B. Song ◽

C. Xu ◽

W. Wang ◽

D. Wang ◽

Y. Zhu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

East Asian ◽

Small Cell ◽

Small Cell Lung ◽

Asian Patients ◽

Notch1 Mutations ◽

P70.11 Prevalence and Clinicopathological Characteristics of ARID1A Mutations in East Asian Patients With Non-Small Cell Lung Cancer

10.1016/j.jtho.2021.08.720 ◽

2021 ◽

Vol 16 (10) ◽

pp. S1214-S1215

Author(s):

C. Xu ◽

W. Wang ◽

D. Wang ◽

Y. Zhu ◽

W. Zhuang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

East Asian ◽

Clinicopathological Characteristics ◽

Small Cell ◽

Small Cell Lung ◽

Asian Patients ◽

P45.06 Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer

10.1016/j.jtho.2021.08.474 ◽

2021 ◽

Vol 16 (10) ◽

pp. S1087

Author(s):

Y. Wu ◽

S. Lu ◽

J.C. Yang ◽

J. Zhou ◽

T. Seto ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Small Cell Lung Cancer ◽

East Asian ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Asian Patients ◽

Phase 2 Study ◽